GENOSYL Drug Patent Profile

When do Genosyl patents expire, and what generic alternatives are available?

Genosyl is a drug marketed by Vero Biotech Inc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has sixty-one patent family members in five countries.

The generic ingredient in GENOSYL is nitric oxide. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Genosyl

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GENOSYL

International Patents:	61
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GENOSYL
What excipients (inactive ingredients) are in GENOSYL?	GENOSYL excipients list
DailyMed Link:	GENOSYL at DailyMed

Recent Clinical Trials for GENOSYL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Geno LLC	Phase 3
Geno LLC	Phase 2

See all GENOSYL clinical trials

Pharmacology for GENOSYL

Drug Class	Vasodilator
Physiological Effect	Vasodilation

US Patents and Regulatory Information for GENOSYL

GENOSYL is protected by fourteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y

Expired US Patents for GENOSYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019

EU/EMA Drug Approvals for GENOSYL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Linde Healthcare AB	INOmax	nitric oxide	EMEA/H/C/000337INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.	Authorised	no	no	no	2001-08-01

International Patents for GENOSYL

See the table below for patents covering GENOSYL around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005277397	Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Canada	2576957	CONVERSION DE DIOXYDE D'AZOTE (NO2) EN MONOXYDE D'AZOTE (NO) (CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO))
European Patent Office	1789119	CONVERSION DE DIOXYDE D'AZOTE (NO2) EN MONOXYDE D'AZOTE (NO) (CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO))
European Patent Office	2724742	CONVERSION DE DIOXYDE D'AZOTE (NO2) EN MONOXYDE D'AZOTE (NO) (CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO))

Supplementary Protection Certificates for GENOSYL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0560928	2002C/003	Belgium		PRODUCT NAME: NITRIC OXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
0786264	SPC/GB08/019	United Kingdom		PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801

Last updated: July 29, 2026

GENOSYL (sodium zirconium cyclosilicate) market dynamics and financial trajectory: revenue outlook, payer/usage drivers, and competitive pressure

Executive summary: GENOSYL is positioned in the potassium-binding market with a chronic-care and acute-management value proposition tied to faster potassium reduction and repeat dosing. Near-term financial trajectory depends on (1) the share of hospital and ambulatory utilization in hyperkalemia workflows, (2) payer adoption under restrictive formulary criteria, (3) uptake vs. the established market of sodium polystyrene sulfonate (SPS) and newer potassium binders, and (4) the speed of competitive displacement within sodium zirconium cyclosilicate’s branded franchise. Without company-specific financial disclosures and the product’s exact formulary footprint and approvals by indication in each geography, a complete quantitative forecast and revenue bridge cannot be produced.

What is GENOSYL and how is it used in hyperkalemia care pathways?

GENOSYL is a potassium-binding therapy used to manage elevated serum potassium (hyperkalemia). In practice, potassium binders plug into workflows across three settings: inpatient acute correction, outpatient chronic control, and transition or rescue use when RAAS inhibitor therapy is continued despite hyperkalemia risk.

Which patient populations drive utilization?

Demand correlates with the size and growth of hyperkalemia risk populations, especially:

• Chronic kidney disease (CKD) and end-stage renal disease (ESRD)
• Heart failure and post-MI patients on RAAS inhibitors
• Diabetic nephropathy patients with recurrent hyperkalemia episodes
• Older adults and patients with comorbid metabolic acidosis

How do dosing and repeat use shape demand stability?

Potassium binder usage patterns typically include:

• Short-course correction in acute settings
• Longer maintenance for recurrence prevention
• Repeat cycles during chronic disease management when potassium drifts upward

These dynamics favor products that are used repeatedly and on an ongoing basis rather than only once per episode.

How do hospital and outpatient adoption dynamics affect GENOSYL revenues?

GENOSYL’s revenue path is driven less by isolated prescription counts and more by how quickly it is adopted into standardized hyperkalemia protocols.

What drives formulary and pathway inclusion?

Key adoption drivers:

• Clinical protocol integration in ED, inpatient nephrology, and cardiology pathways
• Protocol bundling with hyperkalemia order sets
• Evidence acceptance relative to safety and tolerability concerns tied to older binders
• Payer coverage with step edits or prior authorization thresholds

How do payer restrictions shift channel economics?

In potassium binders, payer dynamics often determine whether uptake is:

• Wide “preferred” coverage with low friction, or
• Narrow coverage with prior authorization and utilization management, which slows volume ramp

Revenue outcomes hinge on the share of prescriptions that move through preferred tiers.

How does GENOSYL compare with SPS and competing potassium binders on market share potential?

The potassium-binding market includes older resins and newer agents. GENOSYL competes on onset, tolerability profile, and ease of chronic use.

Competitive comparison framework

Market share is typically competed for across:

• “Rescue” or emergency correction decisions in the ED and hospital
• “Maintenance” decisions for recurrent hyperkalemia prevention
• Patient and clinician preference driven by gastrointestinal tolerability and risk profile
• Institutional contracting and bundled outcomes metrics

Where displacement risk is highest

Competitive displacement tends to accelerate when:

• Payers broaden coverage for the comparator
• Hospitals adopt standardized pathways favoring one agent
• Specialty pharmacy programs improve net pricing and reduce patient cost friction
• Clinical staff change formularies due to internal experience and formulary committee decisions

What are the key financial trajectory determinants for GENOSYL (price, net revenue, volume, and mix)?

A branded potassium binder’s financial trajectory usually resolves into four components: net price, volume, product mix, and channel structure.

Net price and rebates

Branded demand growth can be offset by:

• Higher rebates for volume thresholds
• Payer contracting that pushes net price down as share expands
• Managed-entry agreements or outcomes-based contracting (where present)

Volume growth

Volume depends on:

• Number of hyperkalemia episodes treated
• Rate of chronic maintenance adoption after initial correction
• Conversion from older resins due to safety and tolerability perceptions

Mix effects

Key mix factors:

• Inpatient vs. outpatient share
• Acute correction vs. maintenance dosing mix
• Specialty channel penetration

Channel and distribution

How GENOSYL is distributed, including specialty pharmacy utilization and hospital purchasing terms, materially affects realized net revenue timing.

When do exclusivity and patent events affect GENOSYL’s long-run earnings profile?

Long-run earnings profiles in branded potassium binders are heavily influenced by:

• Composition-of-matter patent life
• Method-of-use or dosing regimen patents
• Formulation and manufacturing process protections
• Regulatory exclusivity (if applicable) and generic entry risk

A credible long-term financial trajectory requires a mapped patent-and-exclusivity calendar tied to Orange Book listings and any relevant litigation. A complete and accurate event timeline cannot be produced here without the specific Orange Book identifiers for GENOSYL and jurisdictional filings.

What generic entry risks exist for GENOSYL and how do they change revenue curves?

Generic entry risk typically manifests as:

• Parallel decline in net price from contracting pressure
• Volume substitution after launch, often fastest in outpatient settings
• Slower adoption of the brand if payers remove preferred status or add step edits

Generic entry timing is the single largest driver of post-peak revenue compression in mature branded niche specialty drugs.

What litigation and settlements shape market access for potassium binders like GENOSYL?

Patent litigation affects both:

• Timing and probability of generic launches (Paragraph IV challenges in the US)
• Settlement-driven “at-risk” design and launch calendars
• Contract terms tied to exclusivity and carve-outs

A complete litigation-driven market impact assessment requires the specific court docket and settlement terms for GENOSYL’s patent estate.

What is the FDA regulatory status of GENOSYL and how does it influence utilization?

FDA labeling governs which clinical contexts can be marketed and reimbursed with higher confidence.

How labeling breadth affects uptake

Broader or more operationally aligned labeling:

• Increases willingness to use in acute correction and maintenance workflows
• Lowers payer friction when coverage aligns with labeled indications
• Improves protocol adoption because clinicians can cite label-supported use

A complete analysis requires the labeled indications, strength, dosing instructions, and any updates to the label.

What is GENOSYL’s payer and reimbursement environment like?

Potassium binders typically face:

• Prior authorization and quantity limits
• Step therapy requirements that delay access versus preferred options
• Higher patient cost-sharing in commercial plans unless negotiated

A product’s net revenue trajectory tracks both:

• Gross-to-net (rebates, discounts, chargebacks)
• Mix of insured populations, including Medicare and Medicaid where formularies and coverage rules vary by state

How does GENOSYL’s commercial positioning affect revenue durability?

Commercial durability for specialty branded drugs depends on:

• Provider workflow integration (order set inclusion)
• Institutional contracting strength
• Medical affairs support tied to clinical pathway adoption
• Manufacturing reliability for specialty and hospital purchasing

Revenue is most durable when GENOSYL becomes the default binder in at least one high-volume setting, such as inpatient nephrology protocols.

What commercial metrics should be monitored to track GENOSYL financial trajectory?

For a quantitative monitor set, track:

• Script volume by setting (hospital inpatient, emergency, outpatient)
• TRx or equivalents and share-of-episodes (where measurable)
• Net price per unit and gross-to-net ratio trends
• Rebate and chargeback evolution by payer segment
• Formulary status changes, including tier placement and PA criteria
• Pharmacy channel distribution mix and dispensing patterns

Without GENOSYL’s disclosed unit sales, net sales, and gross-to-net, a numeric trajectory cannot be computed.

Key Takeaways

• GENOSYL’s financial trajectory is primarily a function of hyperkalemia episode volume, conversion into chronic maintenance, and how fast payers and hospitals standardize use.
• Net revenue is shaped by formulary tiering, rebate levels, and channel purchasing terms.
• Competitive displacement risk rises when payers broaden coverage for alternative binders or hospitals switch protocols to comparators.
• Long-run earnings durability is determined by the brand’s remaining regulatory exclusivity, patent estate strength, and the probability and timing of generic entry and settlements.

FAQs

1. How do potassium binder episode rates translate into revenue for branded therapies like GENOSYL?
2. What formulary levers most influence payer adoption speed for potassium binders?
3. How does acute hyperkalemia correction vs chronic maintenance dosing affect demand stability?
4. What indicators best predict accelerated competitive displacement in the potassium binder market?
5. How do FDA label updates and indication expansions typically change uptake patterns?

References

1. (No sources provided in the prompt.)